Achilles Therapeutics plc (ACHL)
- Previous Close
0.7895 - Open
0.7977 - Bid 0.7225 x 100
- Ask 0.8020 x 100
- Day's Range
0.7400 - 0.8000 - 52 Week Range
0.7400 - 1.7600 - Volume
259,847 - Avg. Volume
771,359 - Market Cap (intraday)
32.134M - Beta (5Y Monthly) 1.09
- PE Ratio (TTM)
-- - EPS (TTM)
-1.7400 - Earnings Date May 8, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
2.83
Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient. It also develops CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.
www.achillestx.comRecent News: ACHL
Performance Overview: ACHL
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ACHL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ACHL
Valuation Measures
Market Cap
32.13M
Enterprise Value
-94.79M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.23
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
1.34
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-24.61%
Return on Equity (ttm)
-41.05%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-69.67M
Diluted EPS (ttm)
-1.7400
Balance Sheet and Cash Flow
Total Cash (mrq)
131.54M
Total Debt/Equity (mrq)
3.24%
Levered Free Cash Flow (ttm)
-28.2M